Spero Therapeutics, Inc.

New Pharma Licence Holdings Limited

Michael Dawson

Pamela Brown

Esther Duperchy

Mona Simonovic

Steven Boakes

Antoinette Wilson

Stephen Frederick Moss

Scott Coleman

Steven James Stanway

Dean Rivers

Roy Lester

The present invention provides a compound of formula (I), and its use in methods of treatment, including the treatment of bacterial infections. Methods for the preparation of the compound of formula (I) are also provided. The compound of formula (I) has the structure shown below, where —Rand —Rare each together with the carbonyl group and nitrogen alpha to the carbon to which it is attached an amino acid residue, except that R6 together with the carbonyl group and nitrogen alpha to the carbon to which it is attached is not a phenylalanine, leucine or valine residue and/or —Rtogether with the carbonyl group and nitrogen alpha to the carbon to which it is attached is not a leucine, iso-leucine, phenylalanine, threonine, valine or nor-valine residue, and -T, -A, -A, -Aand —Rare as discussed in the application:

Polymyxin compounds and uses thereof

The invention provides a polymyxin compound of formula (I) and salts, solvates and protected forms thereof, pharmaceutical compositions comprising the compounds of formula (I), and the use of the compounds and compositions in methods of treatment, such as methods for the treatment of microbial infections. The compounds of formula (I) are represented thus:  

Polymyxin compounds

Described are compounds of formula (I) for use in combination treatment with a second active agent, such as rifampicin, for example for treatment of a microbial infection. The compound of formula (I) is a polymyxin compound is: 

Polymyxin derivatives and their use in combination therapy together with different antibiotics

Growing community of inventors

Reading, United Kingdom

Michael Dawson